AcromegalyEn Español (Spanish Version)
Acromegaly is a rare disorder of excessive bone and soft tissue growth due to elevated levels of growth hormone. In young children, prior to the completed fusion and growth of bones, excessive growth hormone can cause a similar condition called gigantism.
In most cases, acromegaly is caused by over-secretion of growth hormone (GH) produced by a benign tumor of the pituitary gland. The pituitary gland is a small gland located at the base of the brain that produces many hormones. In a small number of cases, malignant tumors of other organs (pancreas, adrenal, lung) may be the source of excess GH.
© 2008 Nucleus Medical Art, Inc.
A risk factor is something that increases your chances of getting a disease or condition. Some rare cases of acromegaly are hereditary. The average age of diagnosis is 40-45 years old.
Symptoms usually develop very slowly over time. Acromegaly can cause serious complications and premature death if not treated.
In children, excess GH production causes elongation of the bones and associated soft tissue swelling. If not treated, children with this disorder can grow to a height of 7-8 feet.
Symptoms and complications in adults may include the following:
Abnormally large growth and deformity of the:
- Hands (rings no longer fit)
- Feet (need a bigger size shoe)
- Face (protrusion of brow and lower jaw)
- Jaw (teeth do not line up correctly when the mouth is closed)
- Carpal tunnel syndrome
Skin changes, such as:
- Thickened, oily, and sometimes darkened skin
- Severe acne
- Excessive sweating and offensive body order due to enlargement of the sweat glands
- Deepening voice due to enlarged sinuses, vocal cords, and soft tissues of the throat
- Fatigue and weakness in legs and arms
- Sleep apnea
- Arthritis and other joint problems especially in the jaw
- Enlargement of the liver, kidneys, spleen, heart, and/or other internal organs, which can lead to:
- Irregular menstrual cycles
- Galactorrhea (abnormal production of breast milk) in about 50% of cases
- Impotence in about 50% of cases
The doctor will ask about your symptoms and medical history, and perform a physical exam. The symptoms of acromegaly develop slowly over a number of years, so it is often not diagnosed until years after its onset.
Blood tests will be done to measure the level of insulin-like growth factor (IGF-I), currently the best screening test, growth hormone releasing hormone (GHRH), and other pituitary hormones. A glucose tolerance test may also be given to see if the GH level drops—it will not drop in cases of acromegaly.
If these tests confirm acromegaly, the following may be done to locate the tumor that is causing the disorder:
The goals of treatment are to:
- Reduce production of GH to normal levels
- Stop and reverse the symptoms caused by oversecretion of GH
- Correct other endocrine abnormalities (thyroid, adrenal, sex organs)
- Reduce the tumor size
Treatment may include:
Surgical removal of the pituitary tumor, or other tumor, that is believed to be causing acromegaly may be done. In most cases, this is the preferred treatment.
Radiotherapy is the use of highly focused external beams of radiation to shrink the tumor. It is used most often used when conventional surgery cannot be used or when medications have failed.
Drugs may be given to reduce the level of GH secretion from the pituitary gland. These include:
- Cabergoline (Dostinex)—given orally
- Pergolide (Permax)—given orally
- Bromocriptine (Parlodel)—may be given before surgery to shrink tumor
- Octreotide (Sandostatin)—given by injections (may be the most effective medication for this condition)
- Pegvisomant—given by injections if not responding to other forms of treatment
Medications must often be combined with other therapies to treat larger tumors affecting surrounding structures.
National Institute of Diabetes & Digestive & Kidney Diseases
Pituitary Network Association
Pituitary Tumor Network Association
BC Health Guide
Abrams P, Alexopoulou O, Abs R, et al. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol. 2007;571-577.
Acromegaly treatment consensus workshop participants: guidelines for acromegaly management. J Clin Endocrinol Metab . 2002; 87:4054-4058.
American Academy of Family Physicians website. Available at: http://www.aafp.org .
Cook DM. AACE Acromegaly Guidelines Taskforce. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endoc Pract . 2004;10:213-225.
Glustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab . 2000;85:526-529.
Melmed S. Medical progress: acromegaly. N Engl J Med . 2006;355:2558-2573.
The Merck Manual of Medical Information . Simon and Schuster; 2000.
National Institute of Diabetes & Digestive & Kidney Diseases website. Available at: http://www.niddk.nih.gov .
Paisley AN, Trainer PJ. Medical treatment in acromegaly. Curr Opin Pharmacol . 2003;3:672-677.
Trainer PJ, Drake WM, Katzneison L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med . 2000; 342:1171-1177.
Last reviewed March 2008 by David Juan, MD
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2011 EBSCO Publishing All rights reserved.